Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 6,733 All time
- Disclosed funding
- $804.6B 4913 disclosed amounts
- Median round
- $12.6M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
BrightHeartCompany profile BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening. BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening. | €11M | Series A | AI | France | Investors | |
| PD Perceptive DiscoveryCompany profile Provides preclinical and translational solutions for oncology and radiopharmaceutical programs Provides preclinical and translational solutions for oncology and radiopharmaceutical programs | $15M | StrategicUndisclosed | Biotech | United Kingdom | Investors | |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGVHBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| F Frete.comCompany profile Frete.com connects shippers, transport companies and truck drivers through a digital road-freight platform. Frete.com connects shippers, transport companies and truck drivers through a digital road-freight platform. | R$150M | FIDC financing commitmentUndisclosed | Logistics | Brazil | Investors | |
| A Develops specialized AI systems for regulated industries | $70M | Series B | AI | United States | Investors | |
| U Provides a global clearing system for tokenised deposits and stablecoins | Undisclosed | StrategicUndisclosed | Fintech | United Kingdom | Investors | |
Nocion TherapeuticsCompany profile Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed | |
| S STRM.BIOCompany profile Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy | $8M | Seed2Seed | Biotech | United States | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $50M | Series A | Healthtech | United States | Investors | |
| MT Develops therapies to halt fibrosis in multiple organ systems | $76M | Series B | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Y Combinator (YC)
Unsiloed AI, Model ML, Science Corporation
178rounds5led - 2Andreessen Horowitz (a16z)
Isomorphic Labs, Larridin, Northwood Space
147rounds36led - 3General Catalyst
Rox, Mercor, Clara
142rounds26led - 4NVIDIA
Noeri, Agile Robots, Mercor
103rounds2led - 5Lightspeed
Payhawk, Nominal, Hypersonica
101rounds16led
Latest digests
Archive →Weekly funding picks, November 9–15, 2026
Lucid’s credit commitment, Mercor’s employee tender, factory and clinical robotics, Cocos’s first external capital and Gama’s satellite-power production line.
Browse rounds by topic
Geography
Featured selections
Nahato adds ¥4bn in bank debt for regional and esports expansion
Nahato’s new ¥4bn borrowing brings cumulative financing to ¥10bn. The company plans a Kansai office, recruitment, regional services and gaming expansion.
Read the research →